Foreign Patentee’s Licensing Efforts Satisfy “Commercial Activity” Exception To Federal Sovereign Immunities Act
Client Alert | 1 min read | 07.24.06
In Intel Corp. v. Commonwealth Sci. and Indus. Research Org. (Nos. 06-1032, -1040, July 14, 2006), the Federal Circuit finds the CSIRO's acts of obtaining a U.S. patent and attempting to generate royalty income by licensing the patent were not activities peculiar to a sovereign state under the Federal Sovereign Immunities Act (“FSIA”), but commercial activities that a private entity would engage in.
CSIRO, Australia's national science agency, had attempted to license its patent to certain U.S. companies, who subsequently filed declaratory-judgment actions for non-infringement and invalidity after the respective licensing offers expired. CSIRO moved to dismiss the actions for lack of subject matter jurisdiction, claiming immunity under the FSIA. The Federal Circuit panel rejects CSIRO's argument that the “commercial activity” exception to the FSIA would apply only if its patent license negotiations resulted in a fully-executed, binding contract.
The Federal Circuit also rejects CSIRO's argument that the declaratory-judgment suits are not “based upon” the alleged commercial activity as required under the FSIA. These declaratory-judgment suits, says the panel, are "based on" CSIRO's commercial acts of obtaining and asserting a U.S. patent and, to prevail, plaintiffs must prove that CSIRO attempted to enforce its patent against them. CSIRO's representations as to the scope and validity of the patent during license negotiations are also central to plaintiff's claims.
Insights
Client Alert | 4 min read | 04.23.26
Bipartisan Coalition of State AGs Backs Federal PBM Transparency Rule
In mid-April, a bipartisan coalition of 45 State Attorneys General (AG) submitted a formal letter to the U.S. Department of Labor (DOL) expressing their collective support for a proposed rule (Improving Transparency into Pharmacy Benefit Manager Fee Disclosure, or RIN 1210-AB37), which would — if enacted — impose new disclosure obligations on pharmacy benefit managers (PBM) regulated under the Employee Retirement Income Security Act of 1974 (ERISA).
Client Alert | 5 min read | 04.23.26
Client Alert | 3 min read | 04.23.26
Crowell Tracker of Court Rulings on Legal Privilege and Artificial Intelligence Tools
Client Alert | 2 min read | 04.23.26
Two Lawsuits in One: The Growing Risk of Pairing Biometric Tech With Wage-and-Hour Violations
